Partnership announced for type 2 diabetes health outcome research

A 5-year research partnership between Eli Lilly and Company and the University of Surrey was recently announced to study health outcomes of people living with type 2 diabetes, according to a company press release.

“Living with diabetes is a long and involved journey for patients and their caregivers,” Brad Curtis, PhD, of Lilly Diabetes medical affairs, said in the release. “It’s important for clinicians to understand each step of that journey so patients might have a better chance to reach optimal outcomes. We are honored to collaborate with the University of Surrey on this important project.”

The partnership will focus on adherence to therapy, triggers for initiation of injectable therapy, and understanding the different perspective of health care for professionals and the patients.

“Diabetes is a complex condition to manage, requiring each patient to be treated and supported in a variety of ways,” Simon de Lusignan, MD, PhD, of the University of Surrey said in the release. “Our research uses routine data to help busy clinicians incorporate innovation to routine practice, focusing on those diseases that pose highest risk. By understanding how effectively individual care plans work, we can learn more about how to improve and enhance diabetes care broadly. Our aim is to ensure that those suffering with the disease receive treatments that allow them to continue living their lives in the fullest sense, with effective support in place.”